Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SELIM R BENBADIS

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1710902689
CMS profile
258738
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$318,151.45

460 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
UCB, Inc. $71,263.09 123
SK Life Science, Inc. $65,845.63 91
Neurelis, Inc. $63,011.52 90
JAZZ PHARMACEUTICALS INC. $54,023.66 60
Sumitomo Pharma America, Inc. $20,918.77 34
Catalyst Pharmaceuticals, Inc. $16,836.68 18
LivaNova USA, Inc. $13,086.94 18
Eisai Inc. $10,116.17 21
UCB GmbH $2,625.00 1
Marinus Pharmaceuticals, Inc. $310.51 3
NEUROPACE, INC. $113.48 1

Page 2 of 10; records 51–100 of 460 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SELIM R BENBADIS

NPI 1710902689 · CMS profile ID 258738

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 10; records 51–100 of 460 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710902689?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SELIM R BENBADIS, NPI 1710902689, CMS profile ID 258738. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 10; records 51–100 of 460 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710902689?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). SELIM R BENBADIS, NPI 1710902689, CMS profile ID 258738. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 10; records 51–100 of 460 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710902689?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
SELIM R BENBADIS, NPI 1710902689, CMS profile ID 258738, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 10; records 51–100 of 460 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1710902689?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

460 matching records · $318,151.45 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 460 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 460.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
SK Life Science, Inc. $146.0811/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054731193 CMS
Neurelis, Inc. $3,036.0011/16/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050914007 CMS
SK Life Science, Inc. $68.2411/15/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1054731185 CMS
Neurelis, Inc. $22.7011/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050914005 CMS
Jazz Pharmaceuticals Inc. $137.2411/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086985 CMS
Jazz Pharmaceuticals Inc. $40.0011/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086967 CMS
Jazz Pharmaceuticals Inc. $299.4311/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086961 CMS
Jazz Pharmaceuticals Inc. $299.4411/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086965 CMS
Neurelis, Inc. $291.5611/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913995 CMS
Neurelis, Inc. $508.2811/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913997 CMS
Neurelis, Inc. $9.0011/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913999 CMS
Neurelis, Inc. $3,036.0011/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050914001 CMS
Neurelis, Inc. $3,036.0011/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050914003 CMS
Jazz Pharmaceuticals Inc. $125.0011/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086963 CMS
Jazz Pharmaceuticals Inc. $5.5511/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086981 CMS
Jazz Pharmaceuticals Inc. $681.4011/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086957 CMS
Jazz Pharmaceuticals Inc. $681.4011/08/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086959 CMS
Jazz Pharmaceuticals Inc. $5,310.0011/08/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086989 CMS
Sumitomo Pharma America, Inc. $22.8611/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031009183 CMS
Jazz Pharmaceuticals Inc. $7.6011/06/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086983 CMS
UCB GmbH $2,625.0011/03/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021416153 CMS
Neurelis, Inc. $249.7311/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913993 CMS
UCB, Inc. $20.0311/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021484001 CMS
Catalyst Pharmaceuticals, Inc. $2,240.0011/01/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048225077 CMS
Neurelis, Inc. $121.3611/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913991 CMS
Neurelis, Inc. $298.3210/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913989 CMS
Neurelis, Inc. $114.3810/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913987 CMS
Catalyst Pharmaceuticals, Inc. $3,360.0010/27/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224575 CMS
Catalyst Pharmaceuticals, Inc. $118.0010/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224579 CMS
Catalyst Pharmaceuticals, Inc. $11.5010/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224581 CMS
Catalyst Pharmaceuticals, Inc. $1,120.0010/27/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224585 CMS
Neurelis, Inc. $99.5410/25/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913985 CMS
LivaNova USA, Inc. $109.5210/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042936679 CMS
Jazz Pharmaceuticals Inc. $86.4510/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1059086987 CMS
Neurelis, Inc. $23.5910/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913983 CMS
Catalyst Pharmaceuticals, Inc. $125.0010/17/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224561 CMS
UCB, Inc. $82.6310/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021484103 CMS
Neurelis, Inc. $2,024.0010/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913981 CMS
Catalyst Pharmaceuticals, Inc. $228.6110/12/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224537 CMS
Catalyst Pharmaceuticals, Inc. $120.1810/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224553 CMS
LivaNova USA, Inc. $20.6110/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042936727 CMS
Neurelis, Inc. $3,036.0010/05/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913979 CMS
UCB, Inc. $22.2210/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021484011 CMS
UCB, Inc. $4.3310/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021466353 CMS
Sumitomo Pharma America, Inc. $7.6510/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031009187 CMS
Catalyst Pharmaceuticals, Inc. $1,259.8509/30/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224181 CMS
Catalyst Pharmaceuticals, Inc. $4,000.0009/30/2023 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048224199 CMS
Catalyst Pharmaceuticals, Inc. $218.4009/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048232875 CMS
Catalyst Pharmaceuticals, Inc. $157.3409/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048232867 CMS
Neurelis, Inc. $30.0009/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050913973 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $311,991.58 541
PY2020 $166,691.19 233
PY2021 $310,804.15 408
PY2022 $327,613.75 448
PY2023 $318,151.45 460
PY2024 $334,322.16 486
PY2025 $322,649.03 485

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $118,980.86 47
PY2024 Principal investigator $87,865.69 52
PY2023 Principal investigator $242,936.44 49
PY2022 Principal investigator $98,253.40 16
PY2021 Principal investigator $63,369.44 11
PY2020 Principal investigator $201,909.00 31
PY2019 Principal investigator $197,376.25 31

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

47 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 SK Life Science, Inc. $2,411.50 12/31/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274913
Principal investigator 1 SK Life Science, Inc. $5,185.70 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274983
Principal investigator 1 SK Life Science, Inc. $716.30 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274985
Principal investigator 1 SK Life Science, Inc. $716.30 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274987
Principal investigator 1 SK Life Science, Inc. $650.00 12/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274989
Principal investigator 1 UCB SA $300.00 12/10/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246656826
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,091.53 12/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORID
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223289376
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,810.12 12/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORID
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223289386
Principal investigator 1 SK Life Science, Inc. $5,645.90 12/03/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274981
Principal investigator 1 SK Life Science, Inc. $3,035.80 11/27/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274977
Principal investigator 1 SK Life Science, Inc. $166.67 11/27/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274979
Principal investigator 1 UCB SA $27.89 11/25/2025 Non-covered Recipient Entity
Usf Health South Tampa Center For Advanced Healthcare
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, OUTPATIENT, PARALLEL-GROUP STUDY TO ASSESS THE EFFICACY AND SAFETY OF STACCATO ALPRAZOLAM IN STUDY PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH STEREOTYPICAL PROLONGED SEIZURES No dispute reported 06/30/2026 1246659324
Principal investigator 1 SK Life Science, Inc. $2,674.10 11/21/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274975
Principal investigator 1 SK Life Science, Inc. $1,092.00 11/20/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274973
Principal investigator 1 ABBVIE INC. $4,513.86 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202518469
Principal investigator 1 ABBVIE INC. $1,920.39 10/23/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202518471
Principal investigator 1 H. Lundbeck A S $3,300.00 10/14/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251775619
Principal investigator 1 SK Life Science, Inc. $3,150.00 09/19/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274971
Principal investigator 1 ABBVIE INC. $3,757.50 09/11/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202510810
Principal investigator 1 H. Lundbeck A S $4,750.00 09/09/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251774385
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223284765
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223284767
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,000.00 09/02/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223284769
Principal investigator 1 H. Lundbeck A S $12,850.00 08/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251773900
Principal investigator 1 H. Lundbeck A S $2,500.00 08/26/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathies (DEE) No dispute reported 06/30/2026 1251773905
Principal investigator 1 SK Life Science, Inc. $650.00 08/18/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274925
Principal investigator 1 SK Life Science, Inc. $900.00 06/26/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274931
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $500.00 06/12/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223281178
Principal investigator 1 SK Life Science, Inc. $650.00 05/28/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274933
Principal investigator 1 ABBVIE INC. $1,000.00 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202485999
Principal investigator 1 ABBVIE INC. $3,666.67 05/22/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
An Open-label Extension Trial of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202486001
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,290.69 05/21/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution No dispute reported 06/30/2026 1233745578
Principal investigator 1 SK Life Science, Inc. $2,200.00 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274935
Principal investigator 1 SK Life Science, Inc. $4,891.90 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274937
Principal investigator 1 SK Life Science, Inc. $811.20 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274939
Principal investigator 1 SK Life Science, Inc. $2,200.00 05/12/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274941
Principal investigator 1 SK Life Science, Inc. $4,891.90 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274915
Principal investigator 1 SK Life Science, Inc. $1,000.00 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274917
Principal investigator 1 SK Life Science, Inc. $468.00 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274919
Principal investigator 1 SK Life Science, Inc. $650.00 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274921
Principal investigator 1 SK Life Science, Inc. $1,090.80 04/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C033 No dispute reported 06/30/2026 1252274923
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $150.00 04/08/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA
A PHASE 2, PROSPECTIVE, INTERVENTIONAL, OPEN-LABEL, MULTI-SITE, EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND TOLERABILITY OF TAK-935 (OV935) AS ADJUNCTIVE THERAPY IN PATIENTS WITH RARE EPILEPSY No dispute reported 06/30/2026 1223277646
Principal investigator 1 UCB SA $1,200.00 03/21/2025 Non-covered Recipient Entity
UC IRVINE MEDICAL CENTER- ALS & NEUROMUSCULAR CENTER
An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato alprazolam in STUDY participants 12 years of age and older with stereotypical prolonged seizures No dispute reported 06/30/2026 1246656396
Principal investigator 1 ABBVIE INC. $4,270.00 02/27/2025 Non-covered Recipient Entity
THE UNIVERSITY OF SOUTH FLORIDA BOARD OF TRUSTEES
A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures No dispute reported 06/30/2026 1202455041
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,887.04 01/30/2025 Non-covered Recipient Entity
UNIVERSITY OF SOUTH FLORIDA
A Long-term Safety Study to Assess the Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution No dispute reported 06/30/2026 1233745580
Principal investigator 1 SK Life Science, Inc. $2,247.10 01/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274927
Principal investigator 1 SK Life Science, Inc. $5,100.00 01/30/2025 Non-covered Recipient Entity
University of South Florida
YKP3089C025 No dispute reported 06/30/2026 1252274929